Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Preparation method and application of liposome composite material for light-controlled release of tungsten sulfide quantum dots and vancomycin

A technology of vancomycin and light-controlled release, which is applied in the application of antibacterial reagents, preparation of liposome composite materials, and the field of antibacterial reagents, and can solve problems such as limiting the application of CDT

Inactive Publication Date: 2020-11-27
THE FIRST AFFILIATED HOSPITAL OF ANHUI MEDICAL UNIV
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, high Fenton reaction rate requires strong acid conditions, which limits the application of CDT in living organisms

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method and application of liposome composite material for light-controlled release of tungsten sulfide quantum dots and vancomycin
  • Preparation method and application of liposome composite material for light-controlled release of tungsten sulfide quantum dots and vancomycin
  • Preparation method and application of liposome composite material for light-controlled release of tungsten sulfide quantum dots and vancomycin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] A light-controlled release WS 2 The preparation method of the liposome composite material of QDs and vancomycin, the specific preparation method comprises the following steps:

[0046] Step 1: Dissolving dipalmitoylphosphatidylcholine, cholesterol and distearoylphosphatidylethanolamine-polyethylene glycol-hydroxyl in chloroform at a molar ratio of 20:10:1, and ultrasonically assisted dissolution, Subsequently, by vacuum drying for 30 minutes, a lipid film was obtained on the inner wall of the reaction vessel;

[0047] Step 2: Dissolve tungsten sulfide quantum dots and vancomycin in PBS buffer, then add the PBS buffer containing tungsten sulfide quantum dots and vancomycin into the reaction vessel containing lipid film, and vortex at 45°C Rotate and shake for 1 hour to obtain a hydration solution;

[0048] Step 3: The obtained hydration solution is ultrasonically treated, the ultrasonic power is 60W, and the ultrasonic time is 5 minutes. Finally, it is centrifuged and ...

Embodiment 2

[0050] The invention also provides a light-controlled release WS 2 The application of the liposome composite material of QDs and vancomycin, the method prepared in the embodiment one prepares a kind of liposome composite material of light-controlled release tungsten sulfide quantum dot and vancomycin, namely WS 2 QDs - Van @lipo.

[0051] The application of the antibacterial composite material, the liposome composite material of light-controlled release of tungsten sulfide quantum dots and vancomycin, under near-infrared light and low dose H 2 o 2 Under certain conditions, it has broad-spectrum antibacterial activity against bacteria including but not limited to Escherichia coli and vancomycin-resistant Staphylococcus aureus.

[0052] The application of the antibacterial composite material, the liposome composite material of light-controlled release of tungsten sulfide quantum dots and vancomycin, under near-infrared light and low dose H 2 o 2 Under certain conditions, it ...

Embodiment 3

[0054] Refer to the attached Figure 1-4 Shown:

[0055] In the release of WS on light control 2 During the preparation of liposome composites of QDs and vancomycin, WS 2 QDs-Van@lipo; WS characterized using cryo-electron microscopy 2 The morphology and size of QDs-Van@lipo, found that the nanoparticles are uniform spherical, with an average size of less than 100nm;

[0056] Subsequent to WS 2 Hydrated particle size (DLS) measurement by QDs-Van@lipo, WS 2 The average particle size measured by QDs-Van@lipo is about 146.37±0.67nm;

[0057] to WS 2 Zeta Potential Measurements by QDs-Van@lipo, WS 2 The measured surface zeta potentials of QDs-Van@lipo are -35.4 mV, respectively, and these results confirm the designed WS 2 Successful synthesis of QDs-Van@lipo nanomaterials.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of antibacterial drugs, and discloses a preparation method and application of a liposome composite material for light-controlled release of tungsten sulfide quantumdots and vancomycin. The material is called WS2QDs-Van@lipo for short, wherein WS2QDs are the tungsten sulfide quantum dots, Van is the vancomycin, and lipo is liposome. The preparation method comprises the following steps of firstly, dissolving dipalmitoyl phosphatidylcholine, cholesterol and distearoyl phosphatidylethanolamine-polyethylene glycol-hydroxyl in trichloromethane, and carrying out vacuum drying to generate a lipid film; then, adding the lipid film into PBS containing the WS2QDs and the Van, and performing hydrating to form a thin film; and finally, carrying out ultrasonic treatment after vortex oscillation, and carrying out centrifugal purification to obtain the WS2QDs-Van@lipo composite material. The material can be used as an antibacterial reagent, and can be accurately released at a target part through light control, so that the use amount of antibiotics and the systemic toxicity of organisms are reduced; and the material has a relatively good inhibition effect on theactivity of escherichia coli and vancomycin-resistant staphylococcus aureus, and can provide a safe and effective solution for treatment of refractory drug-resistant bacteria.

Description

technical field [0001] The invention relates to an antibacterial agent, in particular to a method for preparing a liposome composite material of light-controlled release of tungsten sulfide quantum dots and vancomycin, and its application as an antibacterial agent, belonging to the field of biomedical material preparation. Background technique [0002] Overuse of antibiotics can lead to the emergence of drug-resistant bacteria and threaten public health. Currently, vancomycin is the drug of choice for methicillin-resistant Staphylococcus aureus (MRSA) infection, but the overuse of antibiotics has led to the emergence of vancomycin-resistant Staphylococcus aureus strains (Mu50). As vancomycin-resistant S. aureus evades host immune surveillance and leads to clinically persistent chronic infections that are often difficult to treat. Therefore, it is crucial to design a novel antibacterial strategy. This strategy should have high synergistic antibacterial efficacy, which can i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K41/00A61P31/04A61P17/00A61K38/14
CPCA61K41/0042A61K41/0052A61K38/14A61P31/04A61P17/00Y02A50/30
Inventor 李家斌徐梦冉郜玉峰刘艳艳胡翼戴媛媛郑亚虹陈昊然肖雅
Owner THE FIRST AFFILIATED HOSPITAL OF ANHUI MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products